Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PERMINDER J S BHATIA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1013002328
CMS profile
45675
Location
FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$21,332.91

314 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
SK Life Science, Inc. $8,142.44 15
Allergan, Inc. $3,423.74 15
Biohaven Pharmaceuticals, Inc. $3,334.64 14
BANNER LIFE SCIENCES, LLC $985.71 8
BOSTON SCIENTIFIC CORPORATION $708.05 7
AbbVie Inc. $599.85 30
Teva Pharmaceuticals USA, Inc. $455.47 18
Biogen, Inc. $406.91 16
Novartis Pharmaceuticals Corporation $301.04 21
EMD Serono, Inc. $240.21 11
Kyowa Kirin, Inc. $206.74 11
Eisai Inc. $201.30 14
Alexion Pharmaceuticals, Inc. $197.91 14
Supernus Pharmaceuticals, Inc. $175.36 13
Mallinckrodt Hospital Products Inc. $167.26 11
LivaNova USA, Inc. $141.51 8
UCB, Inc. $137.87 6
AstraZeneca Pharmaceuticals LP $114.65 7
Sunovion Pharmaceuticals Inc. $93.08 5
Lundbeck LLC $91.95 5
Genentech USA, Inc. $84.75 4
Amneal Pharmaceuticals LLC $82.97 5
Takeda Pharmaceuticals U.S.A., Inc. $76.64 4
ACADIA Pharmaceuticals Inc $75.65 4
Merz Pharmaceuticals, LLC $60.97 2
Amgen Inc. $59.53 2
Adamas Pharmaceuticals, Inc. $59.46 3
CSL Behring $55.89 3
Horizon Therapeutics plc $54.48 3
Celgene Corporation $51.28 3
GENZYME CORPORATION $50.91 3
E.R. Squibb & Sons, L.L.C. $41.92 2
Neurelis, Inc. $40.81 2
Avanir Pharmaceuticals, Inc. $39.09 2
Zogenix Inc. $36.97 2
Salix Pharmaceuticals, a division of Bausch Health US, LLC $34.02 2
BioDelivery Sciences International, Inc. $33.19 2
Acorda Therapeutics, Inc $26.83 2
Greenwich Biosciences, Inc. $26.39 1
Alnylam Pharmaceuticals Inc. $22.02 1
Merck Sharp & Dohme Corporation $20.60 1
GE HEALTHCARE $19.80 3
Akcea Therapeutics, Inc. $19.67 1
CATALYST PHARMACEUTICALS, INC. $18.53 1
NEUROPACE, INC. $18.49 1
Lilly USA, LLC $18.14 1
ARBOR PHARMACEUTICALS, INC. $17.82 1
UPSHER-SMITH LABORATORIES LLC $16.06 1
AQUESTIVE THERAPEUTICS, INC. $15.46 1
Ipsen Biopharmaceuticals, Inc $14.96 1
PFIZER INC. $13.92 1

Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PERMINDER J S BHATIA

NPI 1013002328 · CMS profile ID 45675

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FRESNO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PERMINDER J S BHATIA, NPI 1013002328, CMS profile ID 45675, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 314 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1013002328?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

314 matching records · $21,332.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 314 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 314.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SK Life Science, Inc. $9.7005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826818981 CMS
Sunovion Pharmaceuticals Inc. $16.5405/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821769577 CMS
Neurelis, Inc. $21.5305/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842860057 CMS
Teva Pharmaceuticals USA, Inc. $16.4705/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839513373 CMS
Teva Pharmaceuticals USA, Inc. $19.9905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839513375 CMS
CATALYST PHARMACEUTICALS, INC. $18.5305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828332659 CMS
LivaNova USA, Inc. $20.2405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844254869 CMS
Biohaven Pharmaceuticals, Inc. $22.1105/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852428231 CMS
Amneal Pharmaceuticals LLC $15.8505/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829646951 CMS
Mallinckrodt Hospital Products Inc. $0.6405/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845346965 CMS
Mallinckrodt Hospital Products Inc. $7.3705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845346967 CMS
BOSTON SCIENTIFIC CORPORATION $89.4205/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777701029 CMS
Biogen, Inc. $20.6905/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827852959 CMS
SK Life Science, Inc. $23.2105/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826818979 CMS
Allergan, Inc. $23.9405/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792708069 CMS
Kyowa Kirin, Inc. $22.5005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852982321 CMS
Novartis Pharmaceuticals Corporation $13.0005/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609533 CMS
Celgene Corporation $17.7105/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783678541 CMS
Alexion Pharmaceuticals, Inc. $3.1305/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783122259 CMS
Amgen Inc. $31.5805/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825683991 CMS
Eisai Inc. $15.4005/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817907505 CMS
Novartis Pharmaceuticals Corporation $16.5805/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609535 CMS
Adamas Pharmaceuticals, Inc. $21.5704/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834395761 CMS
Biohaven Pharmaceuticals, Inc. $1,125.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852428227 CMS
UCB, Inc. $20.5104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807339913 CMS
Biogen, Inc. $18.3404/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827852955 CMS
Teva Pharmaceuticals USA, Inc. $18.7104/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839513371 CMS
EMD Serono, Inc. $14.8804/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849175037 CMS
Novartis Pharmaceuticals Corporation $19.9304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609531 CMS
Sunovion Pharmaceuticals Inc. $18.7204/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821697693 CMS
Kyowa Kirin, Inc. $17.1904/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852982319 CMS
Allergan, Inc. $6.9404/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792708067 CMS
AstraZeneca Pharmaceuticals LP $17.3504/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829861855 CMS
BANNER LIFE SCIENCES, LLC $900.0004/13/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843736887 CMS
Teva Pharmaceuticals USA, Inc. $18.8704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839513369 CMS
Amneal Pharmaceuticals LLC $19.8704/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829646945 CMS
EMD Serono, Inc. $91.8204/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849172207 CMS
Lilly USA, LLC $18.1404/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818686687 CMS
SK Life Science, Inc. $900.0004/08/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826819021 CMS
Acorda Therapeutics, Inc $12.4104/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792552033 CMS
Alexion Pharmaceuticals, Inc. $25.3904/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783122255 CMS
Novartis Pharmaceuticals Corporation $14.4603/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812609529 CMS
LivaNova USA, Inc. $17.2703/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844254851 CMS
Mallinckrodt Hospital Products Inc. $19.3603/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845346963 CMS
UCB, Inc. $21.6703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807338023 CMS
AstraZeneca Pharmaceuticals LP $21.0903/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830105211 CMS
Biogen, Inc. $13.0703/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827852953 CMS
E.R. Squibb & Sons, L.L.C. $18.7103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783438649 CMS
EMD Serono, Inc. $8.8503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849169185 CMS
SK Life Science, Inc. $3,250.0003/22/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826819009 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $17,503.29 211
PY2020 $28,198.74 222
PY2021 $21,332.91 314
PY2022 $22,569.40 284
PY2023 $29,586.01 272
PY2024 $77,400.96 303
PY2025 $82,629.13 327

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,405.53 6
PY2025 Principal investigator $1,597,612.15 218
PY2024 Recipient $1,621.97 3
PY2024 Principal investigator $1,125,524.72 121
PY2023 Recipient $465.64 2
PY2023 Principal investigator $1,137,330.81 86
PY2022 Recipient $3,881.00 3
PY2022 Principal investigator $1,670,191.56 73
PY2021 Recipient $444.81 1
PY2021 Principal investigator $885,391.87 74
PY2020 Principal investigator $653,742.50 69
PY2019 Principal investigator $906,341.06 121

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

224 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,242.56 12/31/2025 Covered Recipient Teaching Hospital
EMORY UNIVERSITY HOSPITAL
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202411598
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202533953
Principal investigator 1 ABBVIE INC. $962.76 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202533955
Principal investigator 1 ABBVIE INC. $582.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202533957
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533959
Principal investigator 1 ABBVIE INC. $828.36 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202533961
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202535381
Principal investigator 1 SK Life Science, Inc. $850.00 12/24/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C025 No dispute reported 06/30/2026 1252274877
Principal investigator 1 SK Life Science, Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C025 No dispute reported 06/30/2026 1252274879
Principal investigator 1 Ipsen Innovation $7,500.00 12/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287682
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 12/17/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045208
Principal investigator 1 ABBVIE INC. $1,224.60 12/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202529024
Principal investigator 1 ABBVIE INC. $1,837.35 12/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202529026
Principal investigator 1 H. Lundbeck A S $2,380.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777903
Principal investigator 1 H. Lundbeck A S $2,006.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777907
Principal investigator 1 H. Lundbeck A S $1,902.00 12/01/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251777912
Principal investigator 1 Ipsen Innovation $689.20 12/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287684
Principal investigator 1 Ipsen Innovation $689.20 12/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287686
Principal investigator 1 Ipsen Pharma SAS $750.00 11/24/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303397
Principal investigator 1 Ipsen Innovation $1,721.33 11/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287680
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045202
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045204
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $838.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045206
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045358
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $838.00 11/19/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045360
Principal investigator 1 ABBVIE INC. $1,820.00 11/13/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202524099
Principal investigator 1 ABBVIE INC. $693.00 11/13/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202524101
Principal investigator 1 ABBVIE INC. $612.30 11/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522053
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287638
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287640
Principal investigator 1 Ipsen Innovation $2,060.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287642
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287644
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287646
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287648
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287650
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287652
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287654
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287656
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287658
Principal investigator 1 Ipsen Innovation $1,565.53 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287660
Principal investigator 1 Ipsen Innovation $1,687.96 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287662
Principal investigator 1 Ipsen Innovation $1,757.21 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287664
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287666
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287668
Principal investigator 1 Ipsen Innovation $2,084.33 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287670
Principal investigator 1 Ipsen Innovation $2,439.64 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287672
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287674
Principal investigator 1 Ipsen Innovation $689.20 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287676
Principal investigator 1 Ipsen Innovation $2,918.50 10/22/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287678
Principal investigator 1 H. Lundbeck A S $327.00 10/15/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775693
Principal investigator 1 SK Life Science, Inc. $1,678.25 10/15/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274845
Principal investigator 1 ABBVIE INC. $15,370.31 10/14/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202516739
Principal investigator 1 ABBVIE INC. $3,105.70 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202515399
Principal investigator 1 ABBVIE INC. $813.70 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516171
Principal investigator 1 ABBVIE INC. $284.85 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202516173
Principal investigator 1 ABBVIE INC. $236.93 10/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202516467
Principal investigator 1 H. Lundbeck A S $7,793.00 10/08/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251775490
Principal investigator 1 Ipsen Innovation $689.20 09/29/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287636
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $632.00 09/24/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067693
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,147.60 09/24/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067695
Principal investigator 1 Roche Products Limited $91.80 09/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628093
Principal investigator 1 H. Lundbeck A S $2,380.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774444
Principal investigator 1 H. Lundbeck A S $1,902.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774449
Principal investigator 1 H. Lundbeck A S $327.00 09/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251774454
Principal investigator 1 ABBVIE INC. $1,837.35 09/04/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202508728
Principal investigator 1 Ipsen Innovation $126.00 08/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287634
Principal investigator 1 ABBVIE INC. $3,939.04 08/13/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202504471
Principal investigator 1 ABBVIE INC. $2,501.55 08/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501800
Principal investigator 1 ABBVIE INC. $1,000.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500472
Principal investigator 1 ABBVIE INC. $560.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500474
Principal investigator 1 ABBVIE INC. $75.00 07/30/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202500476
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287600
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287602
Principal investigator 1 Ipsen Innovation $1,757.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287604
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287606
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287608
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287610
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287612
Principal investigator 1 Ipsen Innovation $1,687.96 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287614
Principal investigator 1 Ipsen Innovation $2,060.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287616
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287618
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287620
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287622
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287624
Principal investigator 1 Ipsen Innovation $1,687.96 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287626
Principal investigator 1 Ipsen Innovation $2,060.21 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287628
Principal investigator 1 Ipsen Innovation $689.20 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287630
Principal investigator 1 Ipsen Innovation $1,910.93 07/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287632
Principal investigator 1 ABBVIE INC. $75.00 07/18/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202498930
Principal investigator 1 SK Life Science, Inc. $2,387.00 07/16/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274835
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,000.00 07/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045200
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 07/11/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045198
Principal investigator 1 ABBVIE INC. $791.10 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202495047
Principal investigator 1 ABBVIE INC. $1,000.00 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202495855
Principal investigator 1 ABBVIE INC. $1,888.90 07/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202495857
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303387
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303389
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303391
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303393
Principal investigator 1 Ipsen Pharma SAS $1,699.65 06/30/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303395
Principal investigator 1 ABBVIE INC. $13,664.00 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493169
Principal investigator 1 ABBVIE INC. $500.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202493183
Principal investigator 1 ABBVIE INC. $163.80 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493185
Principal investigator 1 ABBVIE INC. $2,684.00 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493187
Principal investigator 1 ABBVIE INC. $1,042.60 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493189
Principal investigator 1 ABBVIE INC. $473.20 06/26/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202493191
Principal investigator 1 H. Lundbeck A S $2,000.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease No dispute reported 06/30/2026 1251771661
Principal investigator 1 H. Lundbeck A S $3,300.00 06/26/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Cognitive interview study to evaluate phase 2 trial anchors in patients with Parkinsons Disease No dispute reported 06/30/2026 1251771665
Principal investigator 1 ABBVIE INC. $731.25 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492791
Principal investigator 1 ABBVIE INC. $750.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492793
Principal investigator 1 ABBVIE INC. $843.75 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202492795
Principal investigator 1 Roche Products Limited $306.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628084
Principal investigator 1 Roche Products Limited $306.00 06/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628089
Principal investigator 1 ABBVIE INC. $2,476.18 06/19/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202492445
Principal investigator 1 ABBVIE INC. $594.00 06/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202490587
Principal investigator 1 ABBVIE INC. $3,000.00 06/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202490591
Principal investigator 1 ABBVIE INC. $2,224.20 06/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488051
Principal investigator 1 ABBVIE INC. $43,420.00 05/29/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202487089
Principal investigator 1 Alexion Pharmaceuticals, Inc. $208.00 05/22/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185552095
Principal investigator 1 Ipsen Pharma SAS $1,000.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303381
Principal investigator 1 Ipsen Pharma SAS $750.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303383
Principal investigator 1 Ipsen Pharma SAS $1,500.00 05/19/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303385
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045194
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045196
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045346
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045348
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045350
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045352
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045354
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 05/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045356
Principal investigator 1 Eli Lilly and Company $14,230.00 05/13/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187887066
Principal investigator 1 ABBVIE INC. $3,817.95 05/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483735
Principal investigator 1 ABBVIE INC. $12,802.00 05/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202484029
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,170.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066377
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,500.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066379
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,148.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066381
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,200.00 05/07/2025 Non-covered Recipient Entity
THE CENTER FOR CLINICAL RESEARCH LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066383
Principal investigator 1 ABBVIE INC. $1,960.20 05/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202482245
Principal investigator 1 ABBVIE INC. $1,977.75 05/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202482247
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287556
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287558
Principal investigator 1 Ipsen Innovation $1,687.96 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287560
Principal investigator 1 Ipsen Innovation $1,910.93 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287562
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287564
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287566
Principal investigator 1 Ipsen Innovation $2,559.60 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287568
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287570
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287572
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287574
Principal investigator 1 Ipsen Innovation $2,060.21 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287576
Principal investigator 1 Ipsen Innovation $1,687.96 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287578
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287580
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287582
Principal investigator 1 Ipsen Innovation $2,060.21 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287584
Principal investigator 1 Ipsen Innovation $2,439.64 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287586
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287588
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287590
Principal investigator 1 Ipsen Innovation $1,565.53 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287592
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287594
Principal investigator 1 Ipsen Innovation $689.20 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287596
Principal investigator 1 Ipsen Innovation $2,984.04 04/28/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287598
Principal investigator 1 ABBVIE INC. $2,500.00 04/24/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2) No dispute reported 06/30/2026 1202479409
Principal investigator 1 SK Life Science, Inc. $1,491.85 04/23/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER INC.
YKP3089C049 No dispute reported 06/30/2026 1252274801
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $40,794.72 04/14/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124850
Principal investigator 1 ABBVIE INC. $8,564.50 04/10/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202476103
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,141.30 04/04/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068423
Principal investigator 1 ABBVIE INC. $2,883.40 04/03/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202473635
Principal investigator 1 ABBVIE INC. $1,221.15 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202473827
Principal investigator 1 ABBVIE INC. $2,188.55 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202473831
Principal investigator 1 ABBVIE INC. $2,612.25 04/03/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202473833
Principal investigator 1 Ipsen Pharma SAS $1,699.65 04/01/2025 Non-covered Recipient Entity
Dr Bhatias Neuropain Medical Center
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity No dispute reported 06/30/2026 1184303379
Principal investigator 1 Eli Lilly and Company $256,357.00 03/19/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884890
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 03/14/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045192
Principal investigator 1 ABBVIE INC. $3,211.26 03/13/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463814
Principal investigator 1 ABBVIE INC. $12,052.00 03/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202461275
Principal investigator 1 ABBVIE INC. $6,325.65 03/07/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461279
Principal investigator 1 ABBVIE INC. $1,750.32 03/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202458135
Principal investigator 1 ABBVIE INC. $17,917.93 03/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459047
Principal investigator 1 H. Lundbeck A S $370.36 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768236
Principal investigator 1 H. Lundbeck A S $238.89 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768240
Principal investigator 1 H. Lundbeck A S $123.64 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768244
Principal investigator 1 H. Lundbeck A S $26.05 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768248
Principal investigator 1 H. Lundbeck A S $25.00 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768252
Principal investigator 1 H. Lundbeck A S $126.60 03/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251768256
Principal investigator 1 H. Lundbeck A S $477.01 02/27/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications No dispute reported 06/30/2026 1251767940
Principal investigator 1 Eli Lilly and Company $2,049.50 02/25/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887020
Principal investigator 1 ABBVIE INC. $150.00 02/06/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447521
Principal investigator 1 ABBVIE INC. $1,273.78 02/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202444443
Principal investigator 1 ABBVIE INC. $573.30 02/05/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202446496
Principal investigator 1 ABBVIE INC. $3,291.30 02/05/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202446499
Principal investigator 1 UCB SA $27,104.95 02/05/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246657562
Principal investigator 1 Eli Lilly and Company $615.74 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187884892
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187885654
Principal investigator 1 Eli Lilly and Company $2,720.35 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886984
Principal investigator 1 Eli Lilly and Company $306.56 01/31/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187887064
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $11,896.85 01/31/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066259
Principal investigator 1 Eli Lilly and Company $9,933.14 01/27/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187886204
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045188
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $241.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045190
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045342
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $638.00 01/22/2025 Non-covered Recipient Entity
Neuropain Medical Center Inc
TV50717-CNS-40223 No dispute reported 06/30/2026 1244045344
Principal investigator 1 Eli Lilly and Company $218,226.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187884416
Principal investigator 1 Eli Lilly and Company $56,716.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 1187885290
Principal investigator 1 Eli Lilly and Company $132,434.00 01/21/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187887016
Recipient ACADIA Pharmaceuticals Inc $319.51 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932619
Recipient ACADIA Pharmaceuticals Inc $463.96 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932621
Recipient ACADIA Pharmaceuticals Inc $230.25 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932623
Recipient ACADIA Pharmaceuticals Inc $96.81 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932625
Recipient ACADIA Pharmaceuticals Inc $125.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932627
Recipient ACADIA Pharmaceuticals Inc $170.00 01/17/2025 Covered Recipient Physician ACP-204 No dispute reported 06/30/2026 1245932629
Principal investigator 1 UCB SA $18,220.00 01/17/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246658720
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $190.00 01/14/2025 Non-covered Recipient Entity
Neuro Pain Medical Center Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066257
Principal investigator 1 Eli Lilly and Company $5.79 01/09/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886202
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628063
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628069
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628073
Principal investigator 1 Roche Products Limited $306.00 01/09/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211628078
Principal investigator 1 UCB SA $12,444.90 01/09/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246659398
Principal investigator 1 UCB SA $57,973.45 01/08/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246657333
Principal investigator 1 Eli Lilly and Company $94,433.00 01/07/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187886564
Principal investigator 1 Eli Lilly and Company $114,224.00 01/07/2025 Non-covered Recipient Entity
NEURO PAIN MEDICAL CENTER INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187887018
Principal investigator 1 ABBVIE INC. $4,125.08 01/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202434083
Principal investigator 1 ABBVIE INC. $4,433.40 01/02/2025 Non-covered Recipient Entity
NEURO-PAIN MEDICAL CENTER INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202436304
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $116,355.16 01/01/2025 Non-covered Recipient Entity
NEUROPAIN MEDICAL CENTER
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123704